Last reviewed · How we verify
NCT03170895
Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD
Phase 2 trial testing Sorafenib in AML in 5 participants. Completed in 1 March 2020.
1 February 2020
Quick facts
| Lead sponsor | The University of Hong Kong |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 1 July 2017 |
| Primary completion | 1 February 2020 |
| Estimated completion | 1 March 2020 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Sorafenib (SORAFENIB) — full drug profile →
- Omacetaxine Mepesuccinate Injection — full drug profile →
Conditions studied
- AML — all drugs for AML →
- FLT3-ITD Mutation — all drugs for FLT3-ITD Mutation →
Sponsor
The University of Hong Kong
Who can join
18 and older, any sex, with AML or FLT3-ITD Mutation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to test if combination of sorafenib and omacetaxine mepesuccinate (OM, also known as homoharringtonine) results in durable composite complete remission (CRc) in patients with newly diagnosed or relapsed/refractory (R/R) acute myeloid leukemia (AML) carrying FLT3-ITD (Fms-Like Tyrosine Kinase 3 - Internal Tandem Duplication).
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application.
Seca AML, Pinto DCGA. · · 2018 · cited 331× · PMID 29337925 · DOI 10.3390/ijms19010263 -
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia.
Short NJ, Kantarjian H, Ravandi F, Daver N. · · 2019 · cited 86× · PMID 30800259 · DOI 10.1177/2040620719827310 -
Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
Eguchi M, Minami Y, Kuzume A, Chi S. · · 2020 · cited 54× · PMID 32722298 · DOI 10.3390/biomedicines8080245 -
Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches.
Tecik M, Adan A. · · 2022 · cited 25× · PMID 36474506 · DOI 10.2147/ott.s384293 -
RNA binding protein-directed control of leukemic stem cell evolution and function.
Joshi P, Keyvani Chahi A, Liu L, Moreira S, et al · · 2024 · cited 3× · PMID 39175825 · DOI 10.1002/hem3.116
Verify or expand the search:
- PubMed search for NCT03170895
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sorafenib
Trials testing the same drug.
- NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
- NCT06474663 — A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabi · Phase 1 · withdrawn
- NCT06690697 — Combination of Toripalimab and JS004 Therapy for ccRCC · Phase 2 · recruiting
- NCT06177496 — Influence of Sarcopenia in Hepatocellular Carcinoma Patients · unknown
- NCT05033522 — Immunotherapy for Advanced Liver Cancer · Phase 2, PHASE3 · suspended
Other recruiting trials for AML
Currently open trials in the same condition.
- NCT06611839 — Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML · Phase 1, PHASE2 · recruiting
- NCT07163728 — Leptin: A Marker for AML Chemo-Sensitivity · recruiting
- NCT06973668 — A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophospham · Phase 2 · recruiting
- NCT07126782 — The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT · EARLY_PHASE1 · recruiting
- NCT06717958 — Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute M · Phase 2 · recruiting
Other The University of Hong Kong trials
Trials by the same sponsor.
- NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
- NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
- NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
- NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
- NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03170895 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
- Last refreshed: 30 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03170895.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing